Peptides run from supplements you can buy today to the biggest drugs in metabolic medicine. What they are, how the categories differ, and where to start.
Written bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio
·
The short version
Peptides are short chains of amino acids, and that single chemistry fact stretches across supplements, cosmetics, prescription medicines and research chemicals. Sorting which category you are looking at is the skill that makes everything else readable.
“Peptide” is a chemical class, not a safety or legality stamp.
Clean, prescription, and research products follow different rules.
Start with the bucket and the evidence, then weigh the claims.
A peptide is a short chain of amino acids. That is a statement about chemistry. It says nothing about what a product
does, whether it is legal, or whether it works.
The word covers a lot of ground right now. It takes in a collagen powder in a supermarket, a prescription medicine that
has been through clinical trials, and a vial sold online labelled not for human consumption. All three are peptides. Almost nothing else about them is alike.
This page is the map. It explains what a peptide is, how peptides act in the body, and the three-bucket model I use
across this site to keep these things apart. It also says where the evidence runs out.
What a peptide actually is
Amino acids are small molecules. Link two of them and the bond that forms is called a peptide bond. Link a handful and
you have a peptide; link a great many and the same kind of chain is called a protein. Everything else follows from which
amino acids are in the chain and in what order: the shape it folds into, whether it survives digestion, what it binds
to.
Two examples show the range.
GHK, the peptide at the heart of copper-peptide skincare, is three amino acids: glycine, histidine and lysine.
PubChem lists its molecular formula as C14H24N6O4 and its molecular weight as 340.38 g/mol. Its computed XLogP is −4.4
and its topological polar surface area is 176 Ų. Those numbers describe a very small, very water-loving molecule.
BPC-157, the most talked-about research peptide, is usually described as a synthetic peptide of 15 amino acids. It
is roughly 5 times the length of GHK and behaves nothing like it.
Where peptides stop and proteins start
The peptide/protein boundary is a naming convention, not a law of chemistry. You will see “under 50 amino acids” quoted
confidently across the internet. I could not source that cutoff to an authority I would cite, so I don’t state it as
fact.
The line is arbitrary in practice. Thymosin beta-4 is a 43-amino-acid molecule and is generally called a protein. The
compound sold as TB-500 is Ac-LKKTETQ: a seven-amino-acid, N-acetylated synthetic fragment corresponding to
residues 17 to 23 of thymosin beta-4. It is called a peptide. My source here is a secondary encyclopedia entry, not
a primary paper.
This matters because the fragment is often discussed using the parent protein’s research. A seven-residue fragment may
or may not share the larger protein’s effects, and the studies do not transfer automatically.
How peptides work in the body
Mechanism is where most peptide stories start. It is a good reason to take a compound seriously, but it is only a
starting point. A plausible pathway in a dish earns a compound a human trial. It does not tell you what the trial will
find.
It increased vessel density in chick chorioallantoic membrane and endothelial tube-formation assays.
It upregulated VEGFR2 in cultured human endothelial cells.
It activated a VEGFR2–Akt–eNOS pathway.
It accelerated blood-flow recovery in rat hind-limb ischemia.
The mechanism holds up across three different models (chick membranes, cultured cells and rats). That is the kind of
result that justifies testing it in people.
GHK at 340 Da clears the bar. But its XLogP of −4.4 and TPSA of 176 Ų make it extremely hydrophilic and highly polar.
That on its own works against passive penetration of a lipid barrier. Whether GHK-Cu reaches the living dermis at
cosmetic concentrations in a real person appears never to have been settled empirically. I could not locate a human
penetration study.
The three buckets
This is the model the rest of the site runs on. Open each card.
Collagen & skinReal human trials behind them, and you can buy them today. Sold as supplements or cosmetics.Collagen peptides · Copper peptides (GHK-Cu) · Topical signal peptides
How you'd get it
Buy it in a shop or online today. No prescription, no grey market.
Where it stands legally
Sold legally as supplements (collagen) or cosmetics (topical peptides). Neither category is FDA-approved before sale - that is normal and it is not a scandal, but it does mean the burden of evidence sits with the manufacturer.
Prescription / GLP-1The most studied peptides there are. Approved medicines, large human trials, prescription only.Semaglutide · Tirzepatide
How you'd get it
Through a licensed clinician who assesses whether it is appropriate for you.
Where it stands legally
FDA-approved medicines that have been through clinical trials. Legal, well-studied, and prescription-only for good reason - they have real effects and real side effects.
Research peptidesThe frontier. Striking early findings, mostly in animals, and not approved for human use.BPC-157 · TB-500 · CJC-1295 · Ipamorelin
How you'd get it
Sold online by "research chemical" vendors, labelled not for human use.
Where it stands legally
Not approved for human use in the US. The "research use only" label is the legal basis on which vendors sell at all - it is not a wink, it is the thing that keeps the sale lawful. Purity and contents are not verified by any regulator.
Open one to see how it's sold, and where it stands legally.
The buckets are a reader’s shorthand. The legal spine underneath them is narrower: intended use plus route of
administration.
Federal law defines a drug partly by intended use. A drug is an article intended for the diagnosis, cure, mitigation,
treatment or prevention of disease. It is also an article intended to affect the structure or any function of the body
(FD&C Act §201(g)(1)). A cosmetic is defined by cleansing, beautifying, promoting attractiveness or altering appearance (§201(i)).
FDA states that the law does not recognize any category called “cosmeceuticals”; the term has no meaning under the Act.
Route does the rest of the work. A dietary supplement must be, in the statute’s words, intended for ingestion
(§201(ff)(2)(A)(i)). That one clause defeats most grey-market “it’s just a supplement” framing, and it needs no
peptide-specific ruling. An injectable peptide cannot lawfully be marketed as a dietary supplement, whatever the
ingredient.
Bucket one: the clean peptides
US legal status - Dietary supplement
Regulated as a dietary supplement in the US. Supplements are not FDA-approved; manufacturers are responsible for their own safety and labelling, and the FDA acts only after a problem surfaces.
These are the ones you can buy today. The two that matter are ingested collagen and topical cosmetic peptides.
Multiple randomised trials, though with limitations. Multiple double-blind randomized trials and two meta-analyses in over 1,100 participants each, for oral collagen and skin. Effects are statistically real, small in size, and inconsistent across endpoints; much of the flagship literature carries manufacturer-affiliated co-authors.
The 2026 peptide meta-analysis included zero GHK-Cu trials. GHK-Cu is never mentioned anywhere in the paper, so that
review is silent on copper peptides rather than evidence against them. See peptides for skin.
Bucket two: the prescription peptides
US legal status - FDA-approved · prescription only
An FDA-approved prescription medicine. It has been through clinical trials for its approved use, and legally requires a prescription from a licensed clinician.
The GLP-1 medicines, semaglutide and tirzepatide, are peptides too. They are the reason the word is in the culture at
all. They have been through clinical trials, they are FDA-approved, and they require a prescription because they have
real effects and real side effects.
The shadow market beside them is the interesting part for this site. As of 31 May 2026, FDA reported 990 adverse event
reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. State-licensed
pharmacies that are not outsourcing facilities are not required to report, so the true count is likely higher.
FDA has also described:
dosing errors from patients measuring and self-administering incorrect doses
fraudulent products labeled with pharmacies that do not exist
counterfeit Ozempic
products arriving warm
FDA’s baseline advice: compounded drugs should only be used in patients whose medical needs cannot be met by an
FDA-approved drug.
Bucket three: the research peptides
US legal status - Research use only
Sold for laboratory research use only. Not approved by the FDA for human use, and cannot be lawfully marketed as a supplement or a medicine. Products sold this way are not made to pharmaceutical quality standards, and their contents are not verified by anyone.
BPC-157, TB-500, CJC-1295, ipamorelin. None is FDA-approved for any indication in the United States. They are sold as
research chemicals, labeled not for human use, and many buyers use them on themselves, a practice that is growing.
NPR reported in February 2026
that synthetic peptides are increasingly popular among biohackers and wellness influencers. STAT described
BPC-157 moving from gym
subcultures to podcasters, wellness clinics and patients whose conditions are not well managed by standard treatment.
That last group explains a lot of the appeal: people with persistent pain, joint problems or conditions their doctors
have struggled to treat are looking for options.
Small or uncontrolled human studies. Too little to settle the question either way. For BPC-157, the largest research-bucket literature: rodent and in vitro work, with the review literature stating efficacy is yet to be confirmed in humans. The human evidence is too small and too underpowered to answer the question: five studies in roughly 80 people, of which the single randomized placebo-controlled trial was null and exists only as a conference abstract.
Three further points people rarely hear:
Under §503A a compounder may only use a bulk drug substance that meets one of three conditions. First, it complies with
an applicable USP or NF monograph. If no monograph exists, it must be a component of an FDA-approved drug. If neither
applies, it must appear on FDA’s 503A bulks list. A substance meeting none of these may not lawfully be used in
compounding.
FDA’s Pharmacy Compounding Advisory Committee met on 23–24 July 2026 to discuss BPC-157, KPV, TB-500 and MOTs-C, and
Emideltide/DSIP, Semax and Epitalon, for possible inclusion on that list. The evaluated use for BPC-157 was
ulcerative colitis, not injury recovery. The committee voted 8-6, with one abstention, to recommend adding BPC-157
(ABC News). The vote is advice, and FDA has not yet published a final decision; my
US peptide regulation tracker follows it.
If you compete: BPC-157 is named in the WADA 2026 Prohibited List under S0, and CJC-1295, ipamorelin and
thymosin-ß4 derivatives including TB-500 are named under S2. All are prohibited at all times.
If you are reconstituting anything, my dosage calculator shows the arithmetic and, more
importantly, where the arithmetic stops helping.
A short word on safety
Safety is a property of a specific molecule, at a specific dose, by a specific route, in a specific person, not of the
word “peptide”. Roughly, the buckets themselves give the ranking. An approved medicine has a known side-effect profile.
A supplement has a long history of ingestion. A research compound has not yet been through a human safety study, and no
regulator checks what is in the vial.
My full treatment, including the regulatory picture and FDA’s own red-flag list for consumers, is in
Are peptides safe?.
What I don’t know
Where the peptide/protein boundary actually sits. Widely quoted, and I could not source it to an authority. Treat any number as a convention.
Whether topical peptides reach the tissue they are supposed to act on. GHK is small enough by the 500 Dalton heuristic and strongly hydrophilic against it. No human penetration study resolving this was located.
What dose of a topical peptide does anything. Products are sold across a wide concentration range. I am not aware of human dose-response data for GHK-Cu.
Whether collagen’s effect is specific to collagen. The flagship trials use carbohydrate placebos rather than an equivalent-protein control, so I could not find a trial testing whether ordinary protein would do the same thing.
Why the 2026 meta-analysis found elasticity inconsistent when elasticity was the older literature’s headline result. Better bias-handling, newer null trials, or different inclusion criteria could explain it. I can’t tell, and it determines how confidently anyone should state the skin claim.
What is actually in a research-peptide vial. I could not locate published analytical work testing purity or contamination of BPC-157 or TB-500 products specifically. Extrapolating from GLP-1 test-buy data would be an inference, so I won’t make it.
Whether independent groups can replicate the BPC-157 findings. The efficacy literature is dominated by one research group. That fact is descriptive and does not prove the findings wrong. The literature alone cannot distinguish a funding gap from a replication problem.
None of these gaps is a reason to panic or to dismiss the field. Each is a reason to distrust total confidence in either
direction, including mine on any claim where I haven’t shown you the source.
Common questions
What are peptides, in one sentence?
A peptide is a short chain of amino acids joined by peptide bonds. That describes chemical structure, not what a product does. It is why a collagen powder, a prescription weight-loss injection and an unapproved research chemical can all be called peptides.
What is the difference between a peptide and a protein?
Both are chains of amino acids. The difference is length, and the cutoff is a convention rather than a fact of chemistry. Thymosin beta-4, a 43-amino-acid molecule, is usually called a protein, while the seven-amino-acid fragment sold as TB-500 is called a peptide. I could not find an authoritative source that fixes a single boundary number, so treat any stated cutoff as a naming convention.
Are peptides legal in the US?
It depends entirely on the peptide, how it is sold, and how it is taken. Collagen is sold lawfully as a dietary supplement and copper peptides as cosmetics. GLP-1 medicines like semaglutide are FDA-approved prescription drugs. Compounds such as BPC-157 are sold for research use only and are not approved for human use. Federal law says a dietary supplement must be intended for ingestion, so an injectable peptide cannot lawfully be marketed as a dietary supplement, whatever the ingredient.
Does the "research use only" label mean a peptide is legal to take?
No. FDA has told peptide sellers that their own websites showed the products were intended as drugs for human use, despite research-use-only labeling. The label describes the seller position, not a safety or legality finding, and no regulator verifies what is in the vial.
Do peptides work?
Some do, some are promising but unproven, and many have not yet been tested in a controlled human trial. FDA-approved peptide medicines have been through clinical trials. Oral collagen has real but modest human evidence. Most research peptides, including BPC-157, have been studied almost entirely in rodents, with consistently positive results. The review literature states that efficacy is yet to be confirmed in humans.
Are peptides safe?
Safety is a property of a specific product at a specific dose by a specific route, not of the word peptide. FDA has reported hundreds of adverse event reports tied to compounded GLP-1 drugs, including dosing errors, and has warned about counterfeit and falsely labeled products. For most research peptides, long-term human safety data does not exist yet.
References (25 sources)
Show
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
